_
BioLineRx Awarded Israeli Government Grant of $21 Million
"BioLineRx Awarded Israeli Government Grant of $21 Million for the Development of Innovative Pre-Clinical Drug Candidates: National Grantee Status Reaffirms BioLineRx's Position as Israel's Leading Specialized Drug Development Company" (2 December 2004, Business Wire)
Leading text: "The Israeli Office of the Chief Scientist yesterday announced the selection of BioLineRx as the sole recipient of a $21 million grant for the development of pre-clinical compounds as part of a special initiative for the advancement of the Israeli Biotech industry. The initiative, launched by the Israeli Ministry of Industry, Trade and Labor, is designed to encourage the further development of innovative projects from Israeli universities, hospitals, research centers and early stage companies.
According to BioLineRx's CEO, Dr. Morris Laster, "BioLineRx's award of this new national status not only provides significant funding for development of additional pre-clinical compounds, but also reaffirms BioLineRx's position as Israel's leading specialized drug development company. The Israeli government's ongoing commitment to the Biotech industry will allow a larger number of innovative therapeutic projects to bridge the existing gap between promising early stage research and the clinical results required for partnering with global pharmaceutical manufacturers."
In the Israeli government's formal announcement released yesterday, Rina Pridor, Program Director, stated: "The BioLineRx group is an extremely professional one, combining rich technological know-how, management with wide ranging experience in the industry, significant financial depth and experience, access to sources of information and other strengths that will allow it to develop biotechnology projects into successful companies and products..." [FullText]
Leading text: "The Israeli Office of the Chief Scientist yesterday announced the selection of BioLineRx as the sole recipient of a $21 million grant for the development of pre-clinical compounds as part of a special initiative for the advancement of the Israeli Biotech industry. The initiative, launched by the Israeli Ministry of Industry, Trade and Labor, is designed to encourage the further development of innovative projects from Israeli universities, hospitals, research centers and early stage companies.
According to BioLineRx's CEO, Dr. Morris Laster, "BioLineRx's award of this new national status not only provides significant funding for development of additional pre-clinical compounds, but also reaffirms BioLineRx's position as Israel's leading specialized drug development company. The Israeli government's ongoing commitment to the Biotech industry will allow a larger number of innovative therapeutic projects to bridge the existing gap between promising early stage research and the clinical results required for partnering with global pharmaceutical manufacturers."
In the Israeli government's formal announcement released yesterday, Rina Pridor, Program Director, stated: "The BioLineRx group is an extremely professional one, combining rich technological know-how, management with wide ranging experience in the industry, significant financial depth and experience, access to sources of information and other strengths that will allow it to develop biotechnology projects into successful companies and products..." [FullText]
posted by Dr.Koudinov @ 24.12.04
0 Comments:
Post a Comment
<< Home